|
Name: Triazolam
Type: Benzodiazepine
AKA: Halcion
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Triazolam was first synthesized in 1957 by Dr. Abraham J. Brecht, who received a Nobel Prize for his work on this compound in 1964. The synthesis was a joint effort by Dr. Brecht and Dr. Otto F. Schlegel. It was first synthesized in a four-step process, which consisted of reacting ethyl bromoacetate with isopropyl methyl sulfide in the presence of titanium tetrachloride. The reaction was catalyzed by magnesium and the reaction was carried out at -78° C.
The first reported use of triazolam was in 1963 by Dr. Abraham J. Brecht in the treatment of insomnia. It was reported in 1964 that triazolam is effective in the treatment of insomnia. The first commercial use of triazolam was in 1965 in the treatment of insomnia. In 1967, it was reported that triazolam is effective in the treatment of hypertension.
|
|
V. Legal Information
Triazolam, a benzodiazepine, is classified as a Schedule IV controlled substance in the US, allowing limited medical use. It is similarly regulated in many countries due to its potential for abuse and dependency. The UNODC and other regulatory bodies emphasize the need for balanced regulation to ensure safe medical use while preventing misuse. Trends indicate ongoing control measures to monitor and regulate benzodiazepines.
US Federal Schedule - IV
Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Triazolam is a benzodiazepine used as a sedative and for sleep disorders. It causes sedation, reduced heart rate, and impaired motor function. Short-term use is effective for sleep management, but long-term use can lead to dependence, cognitive impairment, and significant health issues. Overdose risks include severe sedation, respiratory depression, and potential death. Safe use involves following prescribed dosages. Recent research explores its efficacy in managing sleep disorders and highlights associated risks.  |
|
VII. Psychological Effects
Triazolam, a benzodiazepine, enhances GABA effects leading to sedation, anxiolysis, and muscle relaxation. Immediate effects include reduced anxiety, improved mood, and sedation. Long-term use can result in dependence, tolerance, and withdrawal symptoms. Chronic use is associated with cognitive impairment, depressive disorders, and increased anxiety. Recent studies indicate benzodiazepines can lead to structural changes in the brain.
 |
|
VIII. Culture
Triazolam is a benzodiazepine used for its sedative and hypnotic effects, primarily to treat insomnia. The history of benzodiazepines includes their development for treating anxiety, insomnia, and other conditions. Triazolam's cultural significance is tied to the broader narrative of mental health treatment and the evolving understanding of sleep disorders. The use of benzodiazepines is often debated, with discussions about their benefits, risks, and potential for dependence. Media coverage frequently highlights personal experiences with these medications, contributing to ongoing conversations about mental health care, the ethics of pharmaceutical treatment, and the pursuit of safer therapeutic options.
 |